![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ceftobiprole medocaril, Zevtera, is a novel cephalosporin antibiotic indicated for the treatment of serious bacterial infections in hospitalised patients.
Lead Product(s): Ceftobiprole Medocaril
Therapeutic Area: Infections and Infectious Diseases Product Name: Zevtera
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Advanz Pharma
Deal Size: $846.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition June 01, 2021